Ipsen presents positive data for Cabometyx
Initial detailed results from the CONTACT-02 phase III trial showed a statistically significant benefit in progression-free survival in combination with atezolizumab in metastatic castration-resistant prostate cancer.
In addition, four-year extended follow-up data from the pivotal phase III CheckMate -9ER study confirm the long-term efficacy benefits of nivolumab in combination with sunitinib in advanced renal cell carcinoma.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
Go to the original article.
Contact us to request a correction